Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn's Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling

Overview

Journal Metabolomics

Publisher Springer

Specialty Endocrinology

Date 2018 Apr 24

PMID 29681789

Citations 94

Authors

Elizabeth A Scoville

Margaret M Allaman

Caroline T Brown

Amy K Motley

Sara N Horst

Christopher S Williams

Tatsuki Koyama

Zhiguo Zhao

Dawn W Adams

Dawn B Beaulieu

David A Schwartz

Keith T Wilson

Lori A Coburn

Affiliations

Soon will be listed here.

Abstract

Introduction: Biomarkers are needed in inflammatory bowel disease (IBD) to help define disease activity and identify underlying pathogenic mechanisms. We hypothesized that serum metabolomics, which produces unique metabolite profiles, can aid in this search.

Objectives: The aim of this study was to characterize serum metabolomic profiles in patients with IBD, and to assess for differences between patients with ulcerative colitis (UC), Crohn's disease (CD), and non- IBD subjects.

Methods: Serum samples from 20 UC, 20 CD, and 20 non-IBD control subjects were obtained along with patient characteristics, including medication use and clinical disease activity. Non-targeted metabolomic profiling was performed using ultra-high performance liquid chromatography/mass spectrometry (UPLC-MS/MS) optimized for basic or acidic species and hydrophilic interaction liquid chromatography (HILIC/UPLC-MS/MS).

Results: In total, 671 metabolites were identified. Comparing IBD and control subjects revealed 173 significantly altered metabolites (27 increased and 146 decreased). The majority of the alterations occurred in lipid-, amino acid-, and energy-related metabolites. Comparing only CD and control subjects revealed 286 significantly altered metabolites (54 increased and 232 decreased), whereas comparing UC and control subjects revealed only 5 significantly altered metabolites (all decreased). Hierarchal clustering using significant metabolites separated CD from UC and control subjects.

Conclusions: We demonstrate that a number of lipid-, amino acid-, and tricarboxylic acid (TCA) cycle- related metabolites were significantly altered in IBD patients, more specifically in CD. Therefore, alterations in lipid and amino acid metabolism and energy homeostasis may play a key role in the pathogenesis of CD.

Citing Articles

Patchoulene epoxide mitigates colitis and hepatic damage induced by dextran sulfate sodium by regulating the colonic microbiota and purine metabolism.

Chen L, Xie L, Wang L, Zhan X, Zhuo Z, Jiang S Front Immunol. 2025; 16:1509114.

PMID: 40028318 PMC: 11868103. DOI: 10.3389/fimmu.2025.1509114.

Energy metabolism and the intestinal barrier: implications for understanding and managing intestinal diseases.

Chen S, Shen C, Zeng X, Sun L, Luo F, Wan R Front Microbiol. 2025; 16:1515364.

PMID: 39959156 PMC: 11826063. DOI: 10.3389/fmicb.2025.1515364.

Identifying robust biomarkers for the diagnosis and subtype distinction of inflammatory bowel disease through comprehensive serum metabolomic profiling.

Kim J, Suh D, Park Y, Oh C, Oh S, Kang H Sci Rep. 2025; 15(1):5661.

PMID: 39955397 PMC: 11830085. DOI: 10.1038/s41598-025-90160-7.

Host-microbe multi-omics and succinotype profiling have prognostic value for future relapse in patients with inflammatory bowel disease.

OSullivan J, Patel S, Leventhal G, Fitzgerald R, Laserna-Mendieta E, Huseyin C Gut Microbes. 2025; 17(1):2450207.

PMID: 39812341 PMC: 11740686. DOI: 10.1080/19490976.2025.2450207.

Nutritional Management in Stricturing Crohn's Disease: A Pilot Study.

Cavalcanti E, Marra A, Mileti A, Donghia R, Curlo M, Mastronardi M Nutrients. 2024; 16(23.

PMID: 39683547 PMC: 11644502. DOI: 10.3390/nu16234153.

References

Geboes K, Colombel J, Greenstein A, Jewell D, Sandborn W, Vatn M . Indeterminate colitis: a review of the concept--what's in a name?. Inflamm Bowel Dis. 2008; 14(6):850-7. DOI: 10.1002/ibd.20361. View

Ooi M, Nishiumi S, Yoshie T, Shiomi Y, Kohashi M, Fukunaga K . GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res. 2011; 60(9):831-40. DOI: 10.1007/s00011-011-0340-7. View

Williams H, Willsmore J, Cox I, Walker D, Cobbold J, Taylor-Robinson S . Serum metabolic profiling in inflammatory bowel disease. Dig Dis Sci. 2012; 57(8):2157-65. DOI: 10.1007/s10620-012-2127-2. View

Gnewuch C, Liebisch G, Langmann T, Dieplinger B, Mueller T, Haltmayer M . Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J Gastroenterol. 2009; 15(25):3134-41. PMC: 2705736. DOI: 10.3748/wjg.15.3134. View

Wu G, Morris Jr S . Arginine metabolism: nitric oxide and beyond. Biochem J. 1998; 336 ( Pt 1):1-17. PMC: 1219836. DOI: 10.1042/bj3360001. View

Coburn L, Horst S, Chaturvedi R, Brown C, Allaman M, Scull B . High-throughput multi-analyte Luminex profiling implicates eotaxin-1 in ulcerative colitis. PLoS One. 2013; 8(12):e82300. PMC: 3867379. DOI: 10.1371/journal.pone.0082300. View

Zhang Y, Lin L, Xu Y, Lin Y, Jin Y, Zheng C . 1H NMR-based spectroscopy detects metabolic alterations in serum of patients with early-stage ulcerative colitis. Biochem Biophys Res Commun. 2013; 433(4):547-51. DOI: 10.1016/j.bbrc.2013.03.012. View

Podolsky D . Inflammatory bowel disease. N Engl J Med. 2002; 347(6):417-29. DOI: 10.1056/NEJMra020831. View

Marchesi J, Holmes E, Khan F, Kochhar S, Scanlan P, Shanahan F . Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007; 6(2):546-51. DOI: 10.1021/pr060470d. View

10.

Vermeire S, Van Assche G, Rutgeerts P . Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut. 2006; 55(3):426-31. PMC: 1856093. DOI: 10.1136/gut.2005.069476. View

11.

Dehaven C, Evans A, Dai H, Lawton K . Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminform. 2010; 2(1):9. PMC: 2984397. DOI: 10.1186/1758-2946-2-9. View

12.

Fan F, Mundra P, Fang L, Galvin A, Moore X, Weir J . Lipidomic Profiling in Inflammatory Bowel Disease: Comparison Between Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis. 2015; 21(7):1511-8. DOI: 10.1097/MIB.0000000000000394. View

13.

Sharon P, Stenson W . Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984; 86(3):453-60. View

14.

Schoepfer A, Dehlavi M, Fournier N, Safroneeva E, Straumann A, Pittet V . Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013; 108(11):1744-53. DOI: 10.1038/ajg.2013.248. View

15.

Marion-Letellier R, Savoye G, Beck P, Panaccione R, Ghosh S . Polyunsaturated fatty acids in inflammatory bowel diseases: a reappraisal of effects and therapeutic approaches. Inflamm Bowel Dis. 2013; 19(3):650-61. DOI: 10.1097/MIB.0b013e3182810122. View

16.

Playdon M, Sampson J, Cross A, Sinha R, Guertin K, Moy K . Comparing metabolite profiles of habitual diet in serum and urine. Am J Clin Nutr. 2016; 104(3):776-89. PMC: 4997302. DOI: 10.3945/ajcn.116.135301. View

17.

Shivashankar R, Tremaine W, Harmsen W, Loftus Jr E . Incidence and Prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010. Clin Gastroenterol Hepatol. 2016; 15(6):857-863. PMC: 5429988. DOI: 10.1016/j.cgh.2016.10.039. View

18.

Gothe F, Beigel F, Rust C, Hajji M, Koletzko S, Freudenberg F . Bile acid malabsorption assessed by 7 alpha-hydroxy-4-cholesten-3-one in pediatric inflammatory bowel disease: correlation to clinical and laboratory findings. J Crohns Colitis. 2014; 8(9):1072-8. DOI: 10.1016/j.crohns.2014.02.027. View

19.

Coburn L, Horst S, Allaman M, Brown C, Williams C, Hodges M . L-Arginine Availability and Metabolism Is Altered in Ulcerative Colitis. Inflamm Bowel Dis. 2016; 22(8):1847-58. PMC: 4956554. DOI: 10.1097/MIB.0000000000000790. View

20.

Schroeder K, Tremaine W, Ilstrup D . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317(26):1625-9. DOI: 10.1056/NEJM198712243172603. View